Sam Brusco, Associate Editor07.13.23
Inogen, a company offering respiratory products for the homecare setting, has begun an agreement to buy Physio-Assist, a French, privately held company.
Physio-Assist developed and makes Simeox, a tech-enabled airway clearance device currently used outside the U.S. to treat bronchiecstasis, where the lung’s bronchi become damaged and widened. It’s often present in cystic fibrosis and chronic obstructive pulmonary disease (COPD).
Simeox is used in pulmonary rehab centers, as well as at home. It’s cleared in the EU and is currently being sold in Europe, Asia, and the Middle East.
“This acquisition aligns with our strategy to diversify our portfolio to globally improve patient lives through respiratory care,” Nabil Shabshab, president and CEO of Inogen told the press. “Simeox imminently expands our product offering in EMEA, and potentially in the US to serve COPD and other chronic disease patients who suffer from bronchiectasis with an innovative, non-invasive, and next generation airway clearance solution. We believe this is a compelling transaction, as it expands our addressable market opportunity, enhances our long-term growth and profitability, and is expected to generate an attractive return on investment.”
“I am very excited about Physio-Assist becoming a part of the Inogen organization and view this as a significant milestone in the journey to scale the Simeox differentiated product offerings globally in service of bronchiectasis and cystic fibrosis patients with unmet needs,” added Adrien Mithalal, CEO of Physio-Assist.
Inogen will pay about $32 million in cash for Physio-Assist, along with performance-based milestone payments on achievement of goals related to FDA clearance of Simeox. The total consideration, should all milestones be achieved, will not exceed $45 million.
Bryan Garnier acted as the sole financial advisor to PhysioAssist in its $45 million sale to Inogen.
Physio-Assist developed and makes Simeox, a tech-enabled airway clearance device currently used outside the U.S. to treat bronchiecstasis, where the lung’s bronchi become damaged and widened. It’s often present in cystic fibrosis and chronic obstructive pulmonary disease (COPD).
Simeox is used in pulmonary rehab centers, as well as at home. It’s cleared in the EU and is currently being sold in Europe, Asia, and the Middle East.
“This acquisition aligns with our strategy to diversify our portfolio to globally improve patient lives through respiratory care,” Nabil Shabshab, president and CEO of Inogen told the press. “Simeox imminently expands our product offering in EMEA, and potentially in the US to serve COPD and other chronic disease patients who suffer from bronchiectasis with an innovative, non-invasive, and next generation airway clearance solution. We believe this is a compelling transaction, as it expands our addressable market opportunity, enhances our long-term growth and profitability, and is expected to generate an attractive return on investment.”
“I am very excited about Physio-Assist becoming a part of the Inogen organization and view this as a significant milestone in the journey to scale the Simeox differentiated product offerings globally in service of bronchiectasis and cystic fibrosis patients with unmet needs,” added Adrien Mithalal, CEO of Physio-Assist.
Inogen will pay about $32 million in cash for Physio-Assist, along with performance-based milestone payments on achievement of goals related to FDA clearance of Simeox. The total consideration, should all milestones be achieved, will not exceed $45 million.
Bryan Garnier acted as the sole financial advisor to PhysioAssist in its $45 million sale to Inogen.